TheDaoIndex KDAO2011
3 years 10 months ago
Dr. M Tikly share #rheum challenges & solutions in South Africa:
👉⬆️training to gen. practitioners & nurses, 👉estab outreach clinics
👉lobby local government/political groups
👉use of off-label drugs
👉engage pharma: free meds/clinical trials #ACR22 #GlobalHealth @rheumnow https://t.co/BX2qXk1usN
sheila RHEUMarampa
3 years 10 months ago
Dr. Tikly discusses the solutions to drug access challenges in South Africa in both state and private sectors 👇
🔸Off label use, buyouts, price⬇️, advocacy...
Highly relatable because these are similar challenges we face in the PH @rheumarhyme @doktora_ging
#ACR22 @rheumnow https://t.co/ajshylgtIE
David Liew drdavidliew
3 years 10 months ago
Finally we're starting to get therapies for polymyalgia rheumatica!
The best of PMR therapeutics coming up at #ACR22 (and catch it all @RheumNow): https://t.co/lUPICA3Mim
Dr. John Cush RheumNow
3 years 10 months ago
#ACR22 Presents New Data on JIA Clinical Remission with Combo DMARDSs
New research being presented at #ACR22, demonstrated that polyarticular juvenile idiopathic arthritis patients were more likely to achieve clinical remission with combo DMARDSs.
https://t.co/qmfnEvDedA https://t.co/VhkYlZJG3s
Dr. John Cush RheumNow
3 years 10 months ago
Update: axSpA Recommendations
https://t.co/KaBb11WLQD https://t.co/8kIaa0WuvM
Dr. John Cush RheumNow
3 years 10 months ago
Study of 78 824 adults shows Prevalence of Cannabis use was significantly higher during the pandemic vs before the pandemic in states where it is legalized (but not increase in nonlegal states) esp in adults 18 to 29 and 30 to 54 years https://t.co/ZZzCl7dstj https://t.co/qbQLPhI6I8
Rheumatoid arthritis treatment has come leaps and bounds in recent decades. Gone are the days of gold injections, chemical synovectomies, and physician-mandated bedrest (heaven forbid). Though the marketplace for RA treatments is becoming ever more crowded, there are still unmet needs.
The updated 2022 EULAR recommendations for the management of rheumatoid arthritis (RA) were initially presented by Dr. Josef Smolen at EULAR 2022, and are now in press delineating the most recent developments and perspectives in RA treatment.
Dr. John Cush RheumNow
3 years 10 months ago
FDA issues an Emergency Use Authorization (EUA) for anakinra (Kineret) to treat Hospitalized COVID-19+ Patients with pneumonia requiring supplemental
O2 & ! risk for respiratory failure or increased suPAR levels https://t.co/t5gFULIhCH
Dr. John Cush RheumNow
3 years 10 months ago
Dr. Yuz Yusof will be covering #ACR22 as a RheumNow reporter again. He'll be sharing real-time coverage on SLE, auto-inflammatory and COVID.
Follow @Yuz6Yusof! https://t.co/3rYlIrM54m
Dr. John Cush RheumNow
3 years 10 months ago
Chronic Pain increased from 2010-2919. A cross-sectional study of 46 420 respondents, shows nonpharmacologic Rx increased [aOR 2.72] & was greater than opioids for chronic, but not surgical pain. Govt policy & practice guidelines have helped. https://t.co/31oS0xWRMW https://t.co/IvkDRJQvT8
Dr. John Cush RheumNow
3 years 10 months ago
Sleep Habits study from NHANES - 9004 adults >20 yrs (2017-2020) finds mean sleep duration 7.6 hrs on workdays & 8.2 hrs on free days; 23% slept <7 hrs & 25% went to bed > midnight. Nearly 30% had trouble sleeping (daytime sleepiness 27%) https://t.co/Uc7nL4q3fm https://t.co/qvCwqbsez1
As we approach ACR22, there are many things to be excited about, especially with the reintroduction of in-person attendance. My attention this year is in research being presented in these three areas: ankylosing spondylitis; lupus management and treatment; and, subclinical RA.
Dr. John Cush RheumNow
3 years 10 months ago
Follow RheumNow reporter, Dr. Eric Dein, for real-time #ACR22 coverage! https://t.co/NZkVd2A989
